Recent progress in drug development for fibrodysplasia ossificans progressiva

HIGHLIGHTS

• who: Xinmiao Meng from the College of Arts and Sciences, Cornell University, Ithaca, NY, USA have published the research: Recent progress in drug development for fibrodysplasia ossificans progressiva, in the Journal: (JOURNAL)
• what: Given the promising preclinical studies and its proved safety profile, Phase II/III clinical trials of Rapamycin for randomized, placebo-controlled studies and subsequent open-label extension studies were initiated at Kyoto University Hospital in Japan (UMIN000028429), and the outcomes of this trial has not been publicly released .
• how: The Phase I clinical trial BLU-782 in healthy volunteers to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.